Skip to content


Dr. David Samadi’s Live New Show Focuses on Medicine, Health, and Wellness

In September, Fox News health contributor Dr. David Samadi began hosting a live weekly show called “Sunday Housecall with Dr. David Samadi.” The show can be streamed on Facebook, YouTube, and Twitter, and on The purpose of the show is to present the latest news in health and medicine, and professionals who are proven experts in the fields of medicine, health, and nutrition are welcome to appear on the show. The live broadcast will feature calls and emails from viewers that will be answered by Dr. Samadi and his guests either during or after the show. His show will cover a wide-range of medical issues to give his audience the information they need.

Dr. Samadi is originally from Iran, but he fled the country with his family to escape the Iranian Revolution in 1979. He went to high schools in the U.S., Belgium, and London, and was awarded a full college scholarship based on his hard work toward academic success after fleeing Iran. He attended the State University of New York at Stony Brook where he received a bachelor’s degree in biochemistry. He attended Stony Brook University School of Medicine and graduated with a medical degree in 1994.

Dr. Samadi’s medical training began at Montefiore Medical Center in the Bronx, New York, then in 1996, he began working in proctology at Albert Einstein College of Medicine, which is also in the Bronx. While working at Memorial Sloan Kettering the following year, he completed a fellowship in oncology. Then he went to France, where he completed a fellowship in robotic radical prostatectomy. Once he came back to the U.S., he shifted his focusing to urology and cancer treatment while specializing in kidney, bladder, and prostate cancer.

In addition to his new show and his work as a Fox News contributor, Dr. Samadi is currently the head of the robotic surgery department at Lenox Hill Hospital in New York City. He is also a urology professor at Hofstra North Shore-LIJ School of Medicine. Dr. Samadi has successfully performed thousands of prostate cancer surgeries, he is a frequent guest speaker at medical conferences, and he has had numerous articles published in several medical journals. Dr. Samadi has emerged as a top doctor who strives for excellence in cancer treatment.

Dr. David Samadi’s Social Media:

Therapeutic Remedies with Amicus Therapeutics

Amicus Therapeutics is a renowned research leader in rare as well as orphan ailments. Based in New Jersey, Amicus Therapeutics is a biopharmaceutical firm with a prime focus on the development of technologies utilized in therapy for the treatment of a broad range of illnesses. Primarily, the entity focuses mostly on rare and orphan diseases. Moreover, the emphasis of the Amicus Therapeutics has been given to three core elements as the basis for the development of therapeutic remedies.


Normally, the disease has to be strictly rare, and the technology should have the potential to be of high quality as well as the data available must translate to substantial benefits for the patients. The firm has taken upon itself to cultivate compassionate and personal approaches to patients in addition to their caregivers and the entire family at large. The profound culture has been heavily instrumental in the entity’s focus specifically in the advancement of treatments for CDKL5 deficiency, Epidermolysis Bullosa as well as Lysosomal Storage Disorders.


Amicus Therapeutics has managed to set a patient advocacy forum, Amicus Patient & Professional Advocacy, which partners with numerous stakeholders such as patients, healthcare practitioners, families, and caregivers as well as other concerned parties to deliver top-notch quality support system for individuals living with various rare medical conditions (SeekingAlpha). The firm’s global headquarters are in the United Kingdom’s Buckinghamshire. Moreover, the company has operations in other countries including; France, Italy, Germany, Spain and the Netherlands. The corporate headquarters of Amicus Therapeutics is in Cranbury, New Jersey, USA.


Amicus Therapeutics leverages a team of dedicated professionals, which is led by chair John F. Crowley. John’s experience in therapeutic cure runs back to 1998 when two of his children were sadly diagnosed with a rare and severe neuromuscular disorder, a condition called Pompe Disease. Crowley co-founded the successful Novazyme Pharmaceuticals, which strived to research the Pompe Disease, and was of substantial contribution to saving the lives of his two children. Later, Crowley bought the enterprise and remained as its senior vice president. Thus, Amicus Therapeutics is in the hands of an adeptly qualified, skilled and experienced individual with a significant comprehension of the effects of rare ailments. The company has partnered with numerous organizations over time, and they recently applied a request for authorization to market a drug which is meant to cure Fabry disease, migalastat.

More about Amicus Therapeutics at